A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.
Steroidal compounds with abortifacient activity.
Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites.
A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties.
Non-steroidal chemical compounds with abortifacient activity.
Postcoital contraceptives which owe their effectiveness to synthetic preparations.
Chemical substances that interrupt pregnancy after implantation.
Intentional removal of a fetus from the uterus by any of a number of techniques. (POPLINE, 1978)
Oral contraceptives which owe their effectiveness to synthetic preparations.
Chemical compounds that induce menstruation either through direct action on the reproductive organs or through indirect action by relieving another condition of which amenorrhea is a secondary result. (From Dorland, 27th ed)
Chemical compounds causing LUTEOLYSIS or degeneration.
A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.
The insertion of drugs into the vagina to treat local infections, neoplasms, or to induce labor. The dosage forms may include medicated pessaries, irrigation fluids, and suppositories.
Pregnadienes which have undergone ring contractions or are lacking carbon-18 or carbon-19.
Cytoplasmic proteins that specifically bind glucocorticoids and mediate their cellular effects. The glucocorticoid receptor-glucocorticoid complex acts in the nucleus to induce transcription of DNA. Glucocorticoids were named for their actions on blood glucose concentration, but they have equally important effects on protein and fat metabolism. Cortisol is the most important example.
The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo.
The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS.
Contraceptive substances to be used after COITUS. These agents include high doses of estrogenic drugs; progesterone-receptor blockers; ANTIMETABOLITES; ALKALOIDS, and PROSTAGLANDINS.
Bleeding from blood vessels in the UTERUS, sometimes manifested as vaginal bleeding.
The period in the MENSTRUAL CYCLE that follows OVULATION, characterized by the development of CORPUS LUTEUM, increase in PROGESTERONE production by the OVARY and secretion by the glandular epithelium of the ENDOMETRIUM. The luteal phase begins with ovulation and ends with the onset of MENSTRUATION.
Means of postcoital intervention to avoid pregnancy, such as the administration of POSTCOITAL CONTRACEPTIVES to prevent FERTILIZATION of an egg or implantation of a fertilized egg (OVUM IMPLANTATION).
Compounds that interact with PROGESTERONE RECEPTORS in target tissues to bring about the effects similar to those of PROGESTERONE. Primary actions of progestins, including natural and synthetic steroids, are on the UTERUS and the MAMMARY GLAND in preparation for and in maintenance of PREGNANCY.
Chemical substances or agents with contraceptive activity in females. Use for female contraceptive agents in general or for which there is no specific heading.
Steroids containing the fundamental tetracyclic unit with no methyl groups at C-10 and C-13 and with no side chain at C-17. The concept includes both saturated and unsaturated derivatives.
Compounds that inhibit or prevent the proliferation of CELLS.
The periodic shedding of the ENDOMETRIUM and associated menstrual bleeding in the MENSTRUAL CYCLE of humans and primates. Menstruation is due to the decline in circulating PROGESTERONE, and occurs at the late LUTEAL PHASE when LUTEOLYSIS of the CORPUS LUTEUM takes place.
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.
Period from the onset of true OBSTETRIC LABOR to the complete dilatation of the CERVIX UTERI.
The beginning third of a human PREGNANCY, from the first day of the last normal menstrual period (MENSTRUATION) through the completion of 14 weeks (98 days) of gestation.
Administration of a soluble dosage form by placement under the tongue.
An inactive metabolite of PROGESTERONE by reduction at C5, C3, and C20 position. Pregnanediol has two hydroxyl groups, at 3-alpha and 20-alpha. It is detectable in URINE after OVULATION and is found in great quantities in the pregnancy urine.
Blocking the process leading to OVULATION. Various factors are known to inhibit ovulation, such as neuroendocrine, psychological, and pharmacological agents.
The period from onset of one menstrual bleeding (MENSTRUATION) to the next in an ovulating woman or female primate. The menstrual cycle is regulated by endocrine interactions of the HYPOTHALAMUS; the PITUITARY GLAND; the ovaries; and the genital tract. The menstrual cycle is divided by OVULATION into two phases. Based on the endocrine status of the OVARY, there is a FOLLICULAR PHASE and a LUTEAL PHASE. Based on the response in the ENDOMETRIUM, the menstrual cycle is divided into a proliferative and a secretory phase.
A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.
17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
Acute and chronic neurologic disorders associated with the various neurologic effects of ETHANOL. Primary sites of injury include the brain and peripheral nerves.
Aspiration of the contents of the uterus with a vacuum curette.
Endometrial implantation of EMBRYO, MAMMALIAN at the BLASTOCYST stage.
Abnormal uterine bleeding that is not related to MENSTRUATION, usually in females without regular MENSTRUAL CYCLE. The irregular and unpredictable bleeding usually comes from a dysfunctional ENDOMETRIUM.
Postcoital contraceptives which owe their effectiveness to hormonal preparations.
A pair of highly specialized muscular canals extending from the UTERUS to its corresponding OVARY. They provide the means for OVUM collection, and the site for the final maturation of gametes and FERTILIZATION. The fallopian tube consists of an interstitium, an isthmus, an ampulla, an infundibulum, and fimbriae. Its wall consists of three histologic layers: serous, muscular, and an internal mucosal layer lined with both ciliated and secretory cells.
A synthetic progestational dihydroxy derivative of PROGESTERONE. Its acetonide possesses anti-inflammatory properties.
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system.
A synthetic progestational agent with actions similar to those of PROGESTERONE. This racemic or (+-)-form has about half the potency of the levo form (LEVONORGESTREL). Norgestrel is used as a contraceptive, ovulation inhibitor, and for the control of menstrual disorders and endometriosis.
Drugs that stimulate contraction of the myometrium. They are used to induce LABOR, OBSTETRIC at term, to prevent or control postpartum or postabortion hemorrhage, and to assess fetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (ABORTIFACIENTS). Oxytocics used clinically include the neurohypophyseal hormone OXYTOCIN and certain prostaglandins and ergot alkaloids. (From AMA Drug Evaluations, 1994, p1157)
Termination of pregnancy under conditions allowed under local laws. (POPLINE Thesaurus, 1991)
Excessive uterine bleeding during MENSTRUATION.
An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437)
Devices worn in the vagina to provide support to displaced uterus or rectum. Pessaries are used in conditions such as UTERINE PROLAPSE; CYSTOCELE; or RECTOCELE.
A species of gram-positive bacteria in the family Clostridiaceae, found in INTESTINES and SOIL.
An anti-inflammatory 9-fluoro-glucocorticoid.
A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.
A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.
Cytoplasmic proteins that specifically bind MINERALOCORTICOIDS and mediate their cellular effects. The receptor with its bound ligand acts in the nucleus to induce transcription of specific segments of DNA.

Modulation of oestrogenic effects by progesterone antagonists in the rat uterus. (1/1154)

Antiprogestins can modulate oestrogenic effects in various oestrogen-dependent tissues, dependent on species, tissue, dose and duration of treatment. Enhanced oestrogenic responses to mifepristone and onapristone occur in vitro and in vivo. However, the antiprogestins mifepristone, onapristone, and ZK 137 316 can block the ability of oestradiol to increase endometrial growth in non-human primates. Our purposes were firstly, to decide whether mifepristone and onapristone had direct oestrogenic activity in vitro and in the uterus of spayed and immature rats, and secondly, to discover whether antiprogestins exhibit inhibitory effects on oestrogen action in the uterus in spayed, oestrogen-substituted rats. In transactivation assays, mifepristone induced oestrogenic response, whereas onapristone had only marginal effects on reporter gene transcription. In immature rats, onapristone and mifepristone markedly increased uterine weights, and onapristone, but not mifepristone significantly enhanced endometrial luminal epithelial height, a sensitive oestrogen parameter. Conversely, in spayed and adrenalectomized rats, neither onapristone nor mifepristone changed uterine weights or endometrial morphology, indicating that their effects in immature rats were indirect. In spayed, oestrogen-substituted rats, antiprogestins did not block oestradiol-stimulated endometrial growth and luminal and glandular epithelium were stimulated more after antiprogestin plus oestrogen, than after oestradiol alone. All compounds induced compaction of the uterine stroma. In spayed rats, onapristone and some other 13alpha-configured (type 1) antagonists (ZK 135 569, ZK 131 535) reduced oestradiol-stimulated myometrial proliferation and induced an overall uterine weight reduction in animals treated with oestrogen and antiprogestins, in comparison with oestradiol-treated controls. 13beta- configured (type II) antagonists, including mifepristone, lilopristone and ZK 112 993, were not effective. In the uteri of spayed rats, onapristone was also found to enhance the oestradiol-stimulatory effect on expression of the oestrogen-dependent proto-oncogene, c-fos. In conclusion, antiprogestins do not inhibit, but rather enhance, oestrogen-induced uterine glandular and luminal epithelium in spayed rats, contrary to their effects in primates. The rat model is unsuitable to study endometrial antiproliferative effects of antiprogestins in primate uteri.  (+info)

Altered leucocyte trafficking and suppressed tumour necrosis factor alpha release from peripheral blood monocytes after intra-articular glucocorticoid treatment. (2/1154)

OBJECTIVES: A generalised transient improvement may follow intra-articular administration of glucocorticoids to patients with inflammatory arthropathy. This may represent a systemic anti-inflammatory effect of glucocorticoid released from the joint, mediated through processes such as altered leucocyte trafficking or suppressed release of pro-inflammatory cytokines. Patients, who had received intra-articular injections of glucocorticoids were therefore studied for evidence of these two systemic effects. METHODS: Patients with rheumatoid arthritis were studied. Peripheral blood leucocyte counts, tumour necrosis factor alpha (TNF alpha) release by peripheral blood monocytes, blood cortisol concentrations, and blood methylprednisolone concentration were measured for 96 hours after intra-articular injection of methylprednisolone acetate. RESULTS: Measurable concentrations of methylprednisolone were present in blood for up to 96 hours after injection. Significant suppression of the hypothalamic-pituitary-adrenal axis persisted throughout this time. Altered monocyte and lymphocyte trafficking, as evidenced by peripheral blood monocytopenia and lymphopenia, was apparent by four hours after injection and resolved in concordance with the elimination of methylprednisolone. Granulocytosis was observed at 24 and 48 hours. Release of TNF alpha by endotoxin stimulated peripheral blood monocytes was suppressed at four hours and thereafter. Suppression was maximal at eight hours and was largely reversed by the glucocorticoid antagonist, mifepristone. CONCLUSIONS: After intra-articular injection of methylprednisolone, blood concentrations of glucocorticoid are sufficient to suppress monocyte TNF alpha release for at least four days and to transiently alter leucocyte trafficking. These effects help to explain the transient systemic response to intra-articular glucocorticoids. Suppression of TNF alpha is principally a direct glucocorticoid effect, rather than a consequence of other methylprednisolone induced changes to blood composition.  (+info)

Pituitary adenylate cyclase-activating polypeptide, interleukin-6 and glucocorticoids regulate the release of vascular endothelial growth factor in pituitary folliculostellate cells. (3/1154)

There is increasing evidence that hormones play an important role in the control of endothelial cell function and growth by regulating the production of vascular endothelial growth factor (VEGF). VEGF regulates vascular permeability and represents the most powerful growth factor for endothelial cells. In the normal anterior pituitary, VEGF has been detected only in folliculostellate (FS) cells. In the present study, the regulation of the release of VEGF from FS-like mouse TtT/GF cells, and from FS cells of rat pituitary monolayer cell cultures was investigated using a specific VEGF ELISA. Basal release of VEGF was demonstrated in cultures of both TtT/GF cells and rat pituitary cells. Interestingly, the VEGF secretion was stimulated by both forms of pituitary adenylate cyclase-activating polypeptide (PACAP-38 and PACAP-27), indicating that this hypothalamic peptide regulates endothelial cell function and growth within the pituitary. VEGF secretion was also stimulated by interleukin-6 (IL-6) whereas basal, IL-6- and PACAP-stimulated secretion was inhibited by the synthetic glucocorticoid dexamethasone. The inhibitory action of dexamethasone was reversed by the glucocorticoid receptor antagonist RU486, suggesting that in FS cells functional glucocorticoid receptors mediate the inhibitory action of glucocorticoids on the VEGF secretion. The endocrine and auto-/paracrine control of VEGF production in pituitary FS cells by PACAP, IL-6 and glucocorticoids may play an important role both in angiogenesis and vascular permeability regulation within the pituitary under physiological and pathophysiological conditions.  (+info)

Gestational regulation of granulocyte-colony stimulating factor receptor expression in the human placenta. (4/1154)

A number of cytokines and their receptors are abundantly expressed at the materno-fetal interface and are thought to have a function in the regulation of placentation. Granulocyte-colony stimulating factor (G-CSF) is expressed by stromal cells in both placental tissue and maternal decidua throughout placentation. In this study, we examined the expression of placental G-CSF receptor (G-CSFR) mRNA and protein throughout gestation by ribonuclease protection assays, Western blotting, and immunohistochemistry. The major placental form of G-CSFR mRNA, corresponding to a membrane-bound form of the protein, was present in first-trimester placental tissues; levels decreased in second- and were highest in third-trimester placental tissues. Two placental G-CSFR molecules, 120 kDa and 150 kDa, were detected in first- and third-, but not second-, trimester tissues. The level of the 150-kDa G-CSFR was greater in the third- than in first-trimester samples. These differences were irrespective of whether or not the patients had received prostaglandin E1 analogues, prostaglandin E1 analogues and oxytocin, oxytocin alone, or mifepristone before labor. We demonstrated by immunohistochemistry that interstitial cytotrophoblast in first- and second-trimester decidual tissue and cytotrophoblast in term fetal membranes express G-CSFR. These data demonstrate that the expression of specific forms of placental G-CSFR is strictly cell type- and developmental stage-specific, and they suggest that G-CSFR may be important in decidual invasion of cytotrophoblast and in trophoblast function during placentation.  (+info)

Effects of glucocorticoids on maturation of pig oocytes and their subsequent fertilizing capacity in vitro. (5/1154)

The aim of this study was to assess the possible role of glucocorticoids in the maturation of pig oocytes and their subsequent fertilizing capacity in vitro. Pig cumulus-enclosed oocytes collected from prepubertal gilts were cultured in Waymouth MB752/1 medium supplemented with sodium pyruvate (50 microg/ml), LH (0.5 microg/ml), FSH (0.5 microg/ml), and estradiol-17beta (1 microg/ml) in the presence or absence of cortisol or dexamethasone (DEX) for 24 h; they then were cultured without hormonal supplements in the presence or absence of cortisol or DEX for an additional 16-24 h. Treatment of cumulus-enclosed or denuded oocytes with increasing concentrations of cortisol or DEX for 48 h resulted in a dose-response inhibition of germinal vesicle breakdown (GVB). Increasing duration (12-48 h) of treatment with DEX (10 microg/ml) led to a time-dependent inhibition of GVB, which achieved statistical significance by 12 h. The addition of DEX (10 microg/ml) to maturation medium immediately after culture or at 12 h, 24 h, or 36 h after culture also decreased the percentage of oocytes with GVB. When oocytes were exposed to DEX for 48 h, the maturation rate was reduced. The degree of this reduction was dependent on DEX, and a concentration of DEX higher than 0.1 microg/ml was needed. The inhibitory effect of DEX on the maturation of oocytes was prevented by the glucocorticoid receptor antagonist RU-486. Exposure of oocytes to DEX for 40 h did not prevent sperm penetration, affect the incidence of polyspermy, or decrease the ability of oocytes to form a male pronucleus. The intracellular concentration of glutathione (GSH) in cumulus-enclosed oocytes was 4.4 mM per oocyte. Exposure of oocytes to DEX (0.01-10 microg/ml) had no effect on GSH concentration. These results demonstrate that glucocorticoids directly inhibit the meiotic but not cytoplasmic maturation of pig oocytes in vitro. This inhibitory effect is not mediated through a decrease in the level of intracellular GSH.  (+info)

Once-a-month treatment with a combination of mifepristone and the prostaglandin analogue misoprostol. (6/1154)

In this two centre study, the efficacy of 200 mg mifepristone orally followed 48 h later by 0.4 mg misoprostol orally for menstrual regulation was investigated. The dose of mifepristone was taken the day before the expected day of menstruation. Each volunteer was planned to participate for up to 6 months. A plasma beta human chorionic gonadotrophin (HCG) was measured on the day of mifepristone intake. The study was disrupted prematurely due to low efficacy. In 125 treatment cycles the overall pregnancy rate was 17.6% (22 pregnancies) and the rate of continuing pregnancies (failure) was 4.0%. Eight women discontinued the study due to bleeding irregularities which were seen in 15 cycles (12%). These effects on bleeding pattern made the timing of treatment day difficult. Late luteal phase treatment with a combination of mifepristone and misoprostol is not adequately effective for menstrual regulation.  (+info)

The negative regulation of the rat aldehyde dehydrogenase 3 gene by glucocorticoids: involvement of a single imperfect palindromic glucocorticoid responsive element. (7/1154)

Glucocorticoids repressed the polycyclic aromatic hydrocarbon-dependent induction of Class 3 aldehyde dehydrogenase (ALDH3) enzyme activity and mRNA levels in isolated rat hepatocytes by more than 50 to 80%, with a concentration-dependence consistent with the involvement of the glucocorticoid receptor (GR). No consistent effect on the low basal transcription rate was observed. This effect of glucocorticoids (GC) on polycyclic aromatic hydrocarbon induction was effectively antagonized at the mRNA and protein level by the GR antagonist RU38486. The response was cycloheximide-sensitive, because the protein synthesis inhibitor caused a GC-dependent superinduction of ALDH3 mRNA levels. This suggests that the effects of GC on this gene are complex and both positive and negative gene regulation is possible. The GC-response was recapitulated in HepG2 cells using transient transfection experiments with CAT reporter constructs containing 3.5 kb of 5'-flanking region from ALDH3. This ligand-dependent response was also observed when a chimeric GR (GR DNA-binding domain and peroxisome proliferator-activated receptor ligand-binding domain) was used in place of GR in the presence of the peroxisome proliferator, nafenopin. A putative palindromic glucocorticoid-responsive element exists between -930 and -910 base pairs relative to the transcription start site. If this element was either deleted or mutated, the negative GC-response was completely lost, which suggests that this sequence is responsible, in part, for the negative regulation of the gene. Electrophoretic mobility shift analysis demonstrated that this palindromic glucocorticoid-responsive element is capable of forming a specific DNA-protein complex with human glucocorticoid receptor. In conclusion, the negative regulation of ALDH3 in rat liver is probably mediated through direct GR binding to its canonical responsive element.  (+info)

Conformational change in the human glucocorticoid receptor induced by ligand binding is altered by mutation of isoleucine 747 by a threonine. (8/1154)

Limited proteolysis experiments were performed to study conformation changes induced by ligand binding on in vitro produced wild-type and I747T mutant glucocorticoid receptors. Dexamethasone-induced conformational changes were characterized by two resistant proteolysis fragments of 30 and 27 kDa. Although dexamethasone binding affinity was only slightly altered by the I747T substitution (Roux, S., Terouanne, B., Balaguer, P., Loffreda-Jausons, N., Pons, M., Chambon, P., Gronemeyer, H., and Nicolas, J.-C. (1996) Mol. Endocrinol. 10, 1214-1226), higher dexamethasone concentrations were required to obtain the same proteolysis pattern. This difference was less marked when proteolysis experiments were conducted at 0 degrees C, indicating that a step of the conformational change after ligand binding was affected by the mutation. In contrast, RU486 binding to the wild-type receptor induced a different conformational change that was not affected by the mutation. Analysis of proteolysis fragments obtained in the presence of dexamethasone or RU486 indicated that the RU486-induced conformational change affected the C-terminal part of the ligand binding domain differently. These data suggest that the ligand-induced conformational change occurs via a multistep process. In the first step, characterized by compaction of the ligand binding domain, the mutation has no effect. The second step, which stabilizes the activated conformation and does not occur at 4 degrees C, seems to be a key element in the activation process that can be altered by the mutation. This step could involve modification of the helix H12 position, explaining why the conformation induced by RU486 is not affected by the mutation.  (+info)

Mifepristone is a synthetic steroid that is used in the medical termination of pregnancy (also known as medication abortion or RU-486). It works by blocking the action of progesterone, a hormone necessary for maintaining pregnancy. Mifepristone is often used in combination with misoprostol to cause uterine contractions and expel the products of conception from the uterus.

It's also known as an antiprogestin or progesterone receptor modulator, which means it can bind to progesterone receptors in the body and block their activity. In addition to its use in pregnancy termination, mifepristone has been studied for its potential therapeutic uses in conditions such as Cushing's syndrome, endometriosis, uterine fibroids, and hormone-dependent cancers.

It is important to note that Mifepristone should be administered under the supervision of a licensed healthcare professional and it is not available over the counter. Also, it has some contraindications and potential side effects, so it's essential to have a consultation with a doctor before taking this medication.

Abortifacient agents, steroidal, refer to a type of medication or substance that is capable of inducing abortion or causing the termination of pregnancy by interfering with the implantation and maintenance of the fertilized ovum (embryo) or the development of the placenta. Steroidal abortifacient agents are synthetic derivatives of steroids, which have a similar structure to naturally occurring hormones in the human body.

The most commonly used steroidal abortifacient agent is mifepristone, also known as RU-486. Mifepristone works by blocking the action of progesterone, a hormone that is essential for maintaining pregnancy. By blocking the action of progesterone, mifepristone causes the shedding of the uterine lining and the expulsion of the embryo or fetus from the uterus.

Steroidal abortifacient agents are typically used in the early stages of pregnancy, up to 10 weeks after the last menstrual period. They may be used alone or in combination with other medications, such as misoprostol, which helps to stimulate uterine contractions and expel the embryo or fetus from the uterus.

It is important to note that steroidal abortifacient agents are not the same as emergency contraceptives, which are used to prevent pregnancy after unprotected sexual intercourse. Steroidal abortifacient agents are intended for use in cases where pregnancy has already occurred and is unwanted or poses a risk to the health of the mother or fetus.

Hormone antagonists are substances or drugs that block the action of hormones by binding to their receptors without activating them, thereby preventing the hormones from exerting their effects. They can be classified into two types: receptor antagonists and enzyme inhibitors. Receptor antagonists bind directly to hormone receptors and prevent the hormone from binding, while enzyme inhibitors block the production or breakdown of hormones by inhibiting specific enzymes involved in their metabolism. Hormone antagonists are used in the treatment of various medical conditions, such as cancer, hormonal disorders, and cardiovascular diseases.

Misoprostol is a synthetic prostaglandin E1 analog used in obstetrics and gynecology to prevent and treat ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs), reduce the risk of gastric ulcers in patients taking NSAIDs long term, induce labor, manage postpartum hemorrhage, and cause abortion. It is also used off-label for cervical ripening before gynecologic surgery and to treat miscarriage.

In addition, Misoprostol has been found to be effective in reducing the risk of gastric ulcers and NSAID-induced dyspepsia (upper abdominal pain or discomfort) in patients with rheumatoid arthritis and other inflammatory conditions who require long-term NSAID therapy.

It is important to note that Misoprostol should not be used during pregnancy unless under the supervision of a healthcare provider for specific medical indications, such as preventing or treating stomach ulcers in pregnant women taking NSAIDs or inducing labor. It can cause miscarriage and birth defects if taken during early pregnancy.

Non-steroidal abortifacient agents are medications or substances that can cause abortion by interfering with the normal functioning of the hormones in the reproductive system. These agents do not contain steroids and work primarily by preventing the implantation of a fertilized egg in the uterus or by causing the shedding of the uterine lining, leading to the termination of an early pregnancy.

Examples of non-steroidal abortifacient agents include:

1. Mifepristone (RU-486): This medication works by blocking the action of progesterone, a hormone necessary for maintaining pregnancy. When used in combination with another medication called misoprostol, it can cause an abortion during the early stages of pregnancy.
2. Misoprostol: This medication is primarily used to prevent and treat stomach ulcers but can also be used as an abortifacient agent. It causes uterine contractions and cervical dilation, leading to the expulsion of the contents of the uterus.
3. High-dose estrogen and progestin: These hormones can interfere with the normal functioning of the reproductive system and cause an early abortion when taken in high doses.
4. Herbal remedies: Certain herbs, such as pennyroyal, tansy, and savin, have been used traditionally as abortifacient agents. However, their effectiveness and safety are not well-established, and they can cause serious side effects or even death when taken in large quantities.

It is important to note that the use of non-steroidal abortifacient agents for the purpose of inducing an abortion should only be done under the supervision of a licensed healthcare provider, as there are potential risks and complications associated with their use. Additionally, some of these agents may be restricted or illegal in certain jurisdictions, so it is essential to comply with local laws and regulations regarding their use.

Postcoital contraceptives, also known as emergency contraceptives, are methods used to prevent pregnancy after sexual intercourse. The synthetic postcoital contraceptive is a type of emergency contraception that contains synthetic hormones, such as levonorgestrel or ulipristal acetate. These hormones work by preventing ovulation, inhibiting fertilization, or altering the lining of the uterus to prevent implantation of a fertilized egg.

The most common synthetic postcoital contraceptive is the levonorgestrel emergency contraceptive pill (LNG-ECP), which contains a high dose of the synthetic hormone levonorgestrel. It is usually taken as a single dose within 72 hours (3 days) of unprotected sexual intercourse, but it is most effective when taken as soon as possible after intercourse.

Another synthetic postcoital contraceptive is ulipristal acetate, which is also taken as a single dose but within 120 hours (5 days) of unprotected sexual intercourse. Ulipristal acetate works by delaying ovulation and preventing the fertilized egg from implanting in the uterus.

It's important to note that synthetic postcoital contraceptives are not intended for regular use as a primary form of birth control, but rather as an emergency measure to prevent pregnancy after unprotected sexual intercourse or contraceptive failure. They should be used under the guidance of a healthcare provider and should not be used in place of regular contraception.

An abortifacient agent is a substance or drug that causes abortion by inducing the uterus to contract and expel a fetus. These agents can be chemical or herbal substances, and they work by interfering with the implantation of the fertilized egg in the uterine lining or by stimulating uterine contractions to expel the developing embryo or fetus.

Examples of abortifacient agents include misoprostol, mifepristone, and certain herbs such as pennyroyal, tansy, and black cohosh. It is important to note that the use of abortifacient agents can have serious health consequences, including infection, bleeding, and damage to the reproductive system. Therefore, it is essential to consult with a healthcare provider before using any abortifacient agent.

Induced abortion is a medical procedure that intentionally terminates a pregnancy before the fetus can survive outside the womb. It can be performed either surgically or medically through the use of medications. The timing of an induced abortion is typically based on the gestational age of the pregnancy, with different methods used at different stages.

The most common surgical procedure for induced abortion is vacuum aspiration, which is usually performed during the first trimester (up to 12-13 weeks of gestation). This procedure involves dilating the cervix and using a vacuum device to remove the pregnancy tissue from the uterus. Other surgical procedures, such as dilation and evacuation (D&E), may be used in later stages of pregnancy.

Medical abortion involves the use of medications to induce the termination of a pregnancy. The most common regimen involves the use of two drugs: mifepristone and misoprostol. Mifepristone works by blocking the action of progesterone, a hormone necessary for maintaining pregnancy. Misoprostol causes the uterus to contract and expel the pregnancy tissue. This method is typically used during the first 10 weeks of gestation.

Induced abortion is a safe and common medical procedure, with low rates of complications when performed by trained healthcare providers in appropriate settings. Access to induced abortion varies widely around the world, with some countries restricting or prohibiting the practice entirely.

Oral contraceptives, also known as "birth control pills," are synthetic hormonal medications that are taken by mouth to prevent pregnancy. They typically contain a combination of synthetic versions of the female hormones estrogen and progesterone, which work together to inhibit ovulation (the release of an egg from the ovaries), thicken cervical mucus (making it harder for sperm to reach the egg), and thin the lining of the uterus (making it less likely that a fertilized egg will implant).

There are several different types of oral contraceptives, including combination pills, progestin-only pills, and extended-cycle pills. Combination pills contain both estrogen and progestin, while progestin-only pills contain only progestin. Extended-cycle pills are a type of combination pill that are taken for 12 weeks followed by one week of placebo pills, which can help reduce the frequency of menstrual periods.

It's important to note that oral contraceptives do not protect against sexually transmitted infections (STIs), so it's still important to use barrier methods like condoms if you are at risk for STIs. Additionally, oral contraceptives can have side effects and may not be suitable for everyone, so it's important to talk to your healthcare provider about the potential risks and benefits before starting to take them.

Menstruation-inducing agents, also known as menstrual induction agents or abortifacients, are medications or substances that stimulate or induce menstruation and can potentially lead to the termination of an early pregnancy. These agents work by causing the uterus to contract and expel its lining (endometrium), which is shed during menstruation.

Common menstruation-inducing agents include:

1. Hormonal medications: Combination oral contraceptives, containing both estrogen and progestin, can be used to induce menstruation by causing the uterus to shed its lining after a planned break from taking the medication. This is often used in birth control methods like the "birth control pill pack."
2. Prostaglandins: These are naturally occurring hormone-like substances that can cause the uterus to contract. Synthetic prostaglandin analogs, such as misoprostol (Cytotec), can be used to induce menstruation or early pregnancy termination.
3. Mifepristone: This is a synthetic steroid hormone that blocks progesterone receptors in the body. When used in combination with prostaglandins, it can cause the uterus to contract and expel its lining, leading to an abortion or inducing menstruation.

It's important to note that using menstruation-inducing agents without medical supervision or for purposes other than their intended use may pose health risks and should be avoided. Always consult a healthcare professional before using any medication for this purpose.

Luteolytic agents are substances that cause the breakdown or regression of the corpus luteum, a temporary endocrine structure in the ovary that forms after ovulation and produces progesterone during early pregnancy in mammals. These agents work by inhibiting the secretion of prostaglandins, which are necessary for maintaining the integrity of the corpus luteum. By causing the breakdown of the corpus luteum, luteolytic agents can induce menstruation or cause the termination of an early pregnancy. Examples of luteolytic agents include prostaglandin F2alpha (PGF2α) and its analogs, as well as certain dopamine agonists such as cabergoline. These agents are used in various clinical settings, including reproductive medicine and veterinary medicine.

Levonorgestrel is a synthetic form of the natural hormone progesterone, which is used in various forms of birth control and emergency contraceptives. It works by preventing ovulation (the release of an egg from the ovaries), thickening cervical mucus to make it harder for sperm to reach the egg, and thinning the lining of the uterus to make it less likely for a fertilized egg to implant.

Medically, Levonorgestrel is classified as a progestin and is available in various forms, including oral tablets, intrauterine devices (IUDs), and emergency contraceptive pills. It may also be used to treat endometriosis, irregular menstrual cycles, and heavy menstrual bleeding.

It's important to note that while Levonorgestrel is a highly effective form of birth control when used correctly, it does not protect against sexually transmitted infections (STIs). Therefore, condoms should still be used during sexual activity if there is any risk of STI transmission.

Intravaginal administration refers to the delivery of medications or other substances directly into the vagina. This route of administration can be used for local treatment of vaginal infections or inflammation, or to deliver systemic medication that is absorbed through the vaginal mucosa.

Medications can be administered intravaginally using a variety of dosage forms, including creams, gels, foams, suppositories, and films. The choice of dosage form depends on several factors, such as the drug's physicochemical properties, the desired duration of action, and patient preference.

Intravaginal administration offers several advantages over other routes of administration. It allows for direct delivery of medication to the site of action, which can result in higher local concentrations and fewer systemic side effects. Additionally, some medications may be more effective when administered intravaginally due to their ability to bypass first-pass metabolism in the liver.

However, there are also potential disadvantages to intravaginal administration. Some women may find it uncomfortable or inconvenient to use this route of administration, and there is a risk of leakage or expulsion of the medication. Additionally, certain medications may cause local irritation or allergic reactions when administered intravaginally.

Overall, intravaginal administration can be a useful route of administration for certain medications and conditions, but it is important to consider the potential benefits and risks when choosing this method.

Norpregnadienes are a type of steroid hormone that are structurally similar to progesterone, but with certain chemical groups (such as the methyl group at C10) removed. They are formed through the metabolism of certain steroid hormones and can be further metabolized into other compounds.

Norpregnadienes have been studied for their potential role in various physiological processes, including the regulation of reproductive function and the development of certain diseases such as cancer. However, more research is needed to fully understand their functions and clinical significance.

Glucocorticoid receptors (GRs) are a type of nuclear receptor proteins found inside cells that bind to glucocorticoids, a class of steroid hormones. These receptors play an essential role in the regulation of various physiological processes, including metabolism, immune response, and stress response.

When a glucocorticoid hormone such as cortisol binds to the GR, it undergoes a conformational change that allows it to translocate into the nucleus of the cell. Once inside the nucleus, the GR acts as a transcription factor, binding to specific DNA sequences called glucocorticoid response elements (GREs) located in the promoter regions of target genes. The binding of the GR to the GRE can either activate or repress gene transcription, depending on the context and the presence of co-regulatory proteins.

Glucocorticoids have diverse effects on the body, including anti-inflammatory and immunosuppressive actions. They are commonly used in clinical settings to treat a variety of conditions such as asthma, rheumatoid arthritis, and inflammatory bowel disease. However, long-term use of glucocorticoids can lead to several side effects, including osteoporosis, weight gain, and increased risk of infections, due to the widespread effects of these hormones on multiple organ systems.

The endometrium is the innermost layer of the uterus, which lines the uterine cavity and has a critical role in the menstrual cycle and pregnancy. It is composed of glands and blood vessels that undergo cyclic changes under the influence of hormones, primarily estrogen and progesterone. During the menstrual cycle, the endometrium thickens in preparation for a potential pregnancy. If fertilization does not occur, it will break down and be shed, resulting in menstruation. In contrast, if implantation takes place, the endometrium provides essential nutrients to support the developing embryo and placenta throughout pregnancy.

Progesterone is a steroid hormone that is primarily produced in the ovaries during the menstrual cycle and in pregnancy. It plays an essential role in preparing the uterus for implantation of a fertilized egg and maintaining the early stages of pregnancy. Progesterone works to thicken the lining of the uterus, creating a nurturing environment for the developing embryo.

During the menstrual cycle, progesterone is produced by the corpus luteum, a temporary structure formed in the ovary after an egg has been released from a follicle during ovulation. If pregnancy does not occur, the levels of progesterone will decrease, leading to the shedding of the uterine lining and menstruation.

In addition to its reproductive functions, progesterone also has various other effects on the body, such as helping to regulate the immune system, supporting bone health, and potentially influencing mood and cognition. Progesterone can be administered medically in the form of oral pills, intramuscular injections, or vaginal suppositories for various purposes, including hormone replacement therapy, contraception, and managing certain gynecological conditions.

Postcoital contraceptives, also known as emergency contraception, are methods used to prevent pregnancy after sexual intercourse has already occurred. These methods are most effective when used within 24 hours of unprotected sex, but can still be effective up to 120 hours (5 days) after.

There are two main types of postcoital contraceptives:

1. Emergency contraceptive pills (ECPs): These are high-dose hormonal pills that contain levonorgestrel or ulipristal acetate. Levonorgestrel ECPs are available over-the-counter in many countries, while ulipristal acetate ECPs require a prescription.
2. Copper intrauterine device (IUD): This is a small T-shaped device made of copper that is inserted into the uterus by a healthcare provider. The copper IUD can be used as emergency contraception up to 5 days after unprotected sex, and it also provides ongoing contraception for up to 10 years.

It's important to note that postcoital contraceptives are not intended for regular use as a primary form of contraception. They should only be used in emergency situations where other methods of contraception have failed or were not used. It is also recommended to consult with a healthcare provider before using any form of emergency contraception.

Uterine hemorrhage, also known as uterine bleeding or gynecological bleeding, is an abnormal loss of blood from the uterus. It can occur in various clinical settings such as menstruation (known as menorrhagia), postpartum period (postpartum hemorrhage), or in non-pregnant women (dysfunctional uterine bleeding). The bleeding may be light to heavy, intermittent or continuous, and can be accompanied by symptoms such as pain, dizziness, or fainting. Uterine hemorrhage is a common gynecological problem that can have various underlying causes, including hormonal imbalances, structural abnormalities, coagulopathies, and malignancies. It is important to seek medical attention if experiencing heavy or prolonged uterine bleeding to determine the cause and receive appropriate treatment.

The luteal phase is the second half of the menstrual cycle, starting from ovulation (release of an egg from the ovaries) and lasting until the start of the next menstruation. This phase typically lasts around 12-14 days in a regular 28-day menstrual cycle. During this phase, the remains of the dominant follicle that released the egg transform into the corpus luteum, which produces progesterone and some estrogen to support the implantation of a fertilized egg and maintain the early stages of pregnancy. If pregnancy does not occur, the corpus luteum degenerates, leading to a drop in hormone levels and the start of a new menstrual cycle.

Postcoital contraception, also known as emergency contraception, refers to methods used to prevent pregnancy after sexual intercourse has already occurred. These methods are typically used in situations where regular contraception has failed or was not used, such as in cases of condom breakage or forgotten birth control pills.

There are two main types of postcoital contraception:

1. Emergency contraceptive pill (ECP): Also known as the "morning-after pill," this is a hormonal medication that can be taken up to 5 days after unprotected sex, but it is most effective when taken within 72 hours. There are two types of ECPs available: progestin-only and combined estrogen-progestin. The progestin-only pill is preferred because it has fewer side effects and is just as effective as the combined pill.
2. Copper intrauterine device (IUD): This is a small, T-shaped device made of flexible plastic and copper that is inserted into the uterus by a healthcare provider. The IUD can be inserted up to 5 days after unprotected sex to prevent pregnancy. It is the most effective form of emergency contraception available, and it also provides ongoing protection against pregnancy for up to 10 years, depending on the type of IUD.

It's important to note that postcoital contraception should not be used as a regular method of contraception, but rather as a backup in case of emergencies. It is also not effective in preventing sexually transmitted infections (STIs). Regular contraceptive methods, such as condoms and hormonal birth control, are the best ways to prevent unintended pregnancies and STIs.

Progestins are a class of steroid hormones that are similar to progesterone, a natural hormone produced by the ovaries during the menstrual cycle and pregnancy. They are often used in hormonal contraceptives, such as birth control pills, shots, and implants, to prevent ovulation and thicken the cervical mucus, making it more difficult for sperm to reach the egg. Progestins are also used in menopausal hormone therapy to alleviate symptoms of menopause, such as hot flashes and vaginal dryness. Additionally, progestins may be used to treat endometriosis, uterine fibroids, and breast cancer. Different types of progestins have varying properties and may be more suitable for certain indications or have different side effect profiles.

Contraceptive agents, female, are medications or devices specifically designed to prevent pregnancy in women. They work by interfering with the normal process of ovulation, fertilization, or implantation of a fertilized egg in the uterus. Some common examples of female contraceptive agents include:

1. Hormonal methods: These include combined oral contraceptives (COCs), progestin-only pills, patches, vaginal rings, and hormonal implants. They contain synthetic forms of the female hormones estrogen and/or progesterone, which work by preventing ovulation, thickening cervical mucus to make it harder for sperm to reach the egg, or thinning the lining of the uterus to prevent implantation of a fertilized egg.
2. Intrauterine devices (IUDs): These are small, T-shaped devices made of plastic or copper that are inserted into the uterus by a healthcare provider. They release hormones or copper ions that interfere with sperm movement and prevent fertilization or implantation.
3. Barrier methods: These include condoms, diaphragms, cervical caps, and sponges. They work by physically preventing sperm from reaching the egg.
4. Emergency contraception: This includes medications such as Plan B or Ella, which can be taken up to 5 days after unprotected sex to prevent pregnancy. They work by delaying ovulation or preventing fertilization of the egg.
5. Fertility awareness-based methods (FABMs): These involve tracking a woman's menstrual cycle and avoiding sexual intercourse during her fertile window. Some FABMs also involve using barrier methods during this time.

It is important to note that different contraceptive agents have varying levels of effectiveness, side effects, and risks. Women should consult with their healthcare provider to determine the best method for their individual needs and circumstances.

"Gonanes" is not a recognized medical term. However, in the field of chemistry and pharmacology, gonanes refer to a class of steroidal compounds that have a chemical structure similar to testosterone, which is the primary male sex hormone. These compounds are often used as the basis for developing drugs that can affect the reproductive system or other systems in the body that are influenced by testosterone and its derivatives.

It's important to note that while gonanes may have implications for medical research and drug development, they do not have a specific medical definition in the same way that terms like "myocardial infarction" or "diabetes mellitus" do.

Cytostatic agents are a type of medication used in cancer treatment that work by inhibiting or suppressing the growth and division of cancer cells. Unlike cytotoxic chemotherapy, which kills cancer cells outright, cytostatic agents aim to keep cancer cells from dividing and multiplying, effectively halting or slowing down the progression of the disease.

These agents target specific pathways involved in cell division and growth, such as the cell cycle, DNA replication, or protein synthesis. By interfering with these processes, cytostatic agents can prevent cancer cells from multiplying while minimizing harm to healthy cells.

Examples of cytostatic agents include hormonal therapies, targeted therapies, and some types of immunotherapy. While cytostatic agents may not cure cancer, they can help manage the disease, improve quality of life, and extend survival for patients with advanced or metastatic cancer.

Menstruation is the regular, cyclical shedding of the uterine lining (endometrium) in women and female individuals of reproductive age, accompanied by the discharge of blood and other materials from the vagina. It typically occurs every 21 to 35 days and lasts for approximately 2-7 days. This process is a part of the menstrual cycle, which is under the control of hormonal fluctuations involving follicle-stimulating hormone (FSH), luteinizing hormone (LH), estrogen, and progesterone.

The menstrual cycle can be divided into three main phases:

1. Menstruation phase: The beginning of the cycle is marked by the start of menstrual bleeding, which signals the breakdown and shedding of the endometrium due to the absence of pregnancy and low levels of estrogen and progesterone. This phase typically lasts for 2-7 days.

2. Proliferative phase: After menstruation, under the influence of rising estrogen levels, the endometrium starts to thicken and regenerate. The uterine lining becomes rich in blood vessels and glands, preparing for a potential pregnancy. This phase lasts from day 5 until around day 14 of an average 28-day cycle.

3. Secretory phase: Following ovulation (release of an egg from the ovaries), which usually occurs around day 14, increased levels of progesterone cause further thickening and maturation of the endometrium. The glands in the lining produce nutrients to support a fertilized egg. If pregnancy does not occur, both estrogen and progesterone levels will drop, leading to menstruation and the start of a new cycle.

Understanding menstruation is essential for monitoring reproductive health, identifying potential issues such as irregular periods or menstrual disorders, and planning family planning strategies.

Pregnancy is a physiological state or condition where a fertilized egg (zygote) successfully implants and grows in the uterus of a woman, leading to the development of an embryo and finally a fetus. This process typically spans approximately 40 weeks, divided into three trimesters, and culminates in childbirth. Throughout this period, numerous hormonal and physical changes occur to support the growing offspring, including uterine enlargement, breast development, and various maternal adaptations to ensure the fetus's optimal growth and well-being.

Progesterone receptors (PRs) are a type of nuclear receptor proteins that are expressed in the nucleus of certain cells and play a crucial role in the regulation of various physiological processes, including the menstrual cycle, embryo implantation, and maintenance of pregnancy. These receptors bind to the steroid hormone progesterone, which is produced primarily in the ovaries during the second half of the menstrual cycle and during pregnancy.

Once progesterone binds to the PRs, it triggers a series of molecular events that lead to changes in gene expression, ultimately resulting in the modulation of various cellular functions. Progesterone receptors exist in two main isoforms, PR-A and PR-B, which differ in their size, structure, and transcriptional activity. Both isoforms are expressed in a variety of tissues, including the female reproductive tract, breast, brain, and bone.

Abnormalities in progesterone receptor expression or function have been implicated in several pathological conditions, such as uterine fibroids, endometriosis, breast cancer, and osteoporosis. Therefore, understanding the molecular mechanisms underlying PR signaling is essential for developing novel therapeutic strategies to treat these disorders.

The first stage of labor is the period of time when the cervix dilates (opens) and effaces (thins out). This stage is further divided into two phases: the latent phase and the active phase. During the latent phase, the cervix begins to dilate and may progress slowly or stop and start. Contractions are often mild and irregular during this time. The active phase is characterized by more intense and regular contractions that cause the cervix to dilate more rapidly, typically at a rate of 1 cm per hour in first-time mothers.

The first stage of labor ends when the cervix is fully dilated (10 cm) and effaced, which signals the transition to the second stage of labor. During this stage, the mother begins pushing efforts to deliver the baby. It's important to note that the duration of each phase and the overall length of the first stage of labor can vary widely among individuals.

The first trimester of pregnancy is defined as the period of gestational development that extends from conception (fertilization of the egg by sperm) to the end of the 13th week. This critical phase marks significant transformations in both the mother's body and the growing embryo/fetus.

During the first trimester, the fertilized egg implants into the uterine lining (implantation), initiating a series of complex interactions leading to the formation of the placenta - an organ essential for providing nutrients and oxygen to the developing fetus while removing waste products. Simultaneously, the embryo undergoes rapid cell division and differentiation, giving rise to various organs and systems. By the end of the first trimester, most major structures are present, although they continue to mature and grow throughout pregnancy.

The mother may experience several physiological changes during this time, including:
- Morning sickness (nausea and vomiting)
- Fatigue
- Breast tenderness
- Frequent urination
- Food aversions or cravings
- Mood swings

Additionally, hormonal shifts can cause various symptoms and prepare the body for potential changes in lactation, posture, and pelvic alignment as pregnancy progresses. Regular prenatal care is crucial during this period to monitor both maternal and fetal wellbeing, identify any potential complications early on, and provide appropriate guidance and support throughout the pregnancy.

Sublingual administration refers to a route of delivering medication or other substances through placement under the tongue, allowing for rapid absorption into the bloodstream through the mucous membranes located there. This method can allow for quick onset of action and avoids first-pass metabolism in the liver that may occur with oral administration. Common examples of sublingual medications include nitroglycerin for angina pectoris and certain forms of hormone replacement therapy.

Pregnanediol is a steroid hormone that is produced as a metabolite of progesterone. It is primarily used as a biomarker to measure the exposure to progesterone, particularly in cases where progesterone levels need to be monitored, such as during pregnancy or in certain medical conditions. Pregnanediol can be measured in urine, blood, or other bodily fluids and is often used in clinical and research settings to assess hormonal status. It is important to note that pregnanediol itself does not have any known physiological effects on the body, but rather serves as an indicator of progesterone levels.

Ovulation inhibition is a term used in reproductive medicine to describe the prevention or delay of ovulation, which is the release of a mature egg from the ovaries during the menstrual cycle. This can be achieved through various means, such as hormonal contraceptives (birth control pills, patches, rings), injectable hormones, or intrauterine devices (IUDs) that release hormones.

Hormonal contraceptives typically contain synthetic versions of the hormones estrogen and progestin, which work together to inhibit the natural hormonal signals that trigger ovulation. By suppressing the surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH), these methods prevent the development and release of a mature egg from the ovaries.

In addition to preventing ovulation, hormonal contraceptives can also thicken cervical mucus, making it more difficult for sperm to reach the egg, and thin the lining of the uterus, reducing the likelihood of implantation in case fertilization does occur. It is important to note that while ovulation inhibition is a reliable method of birth control, it may not provide protection against sexually transmitted infections (STIs).

The menstrual cycle is a series of natural changes that occur in the female reproductive system over an approximate 28-day interval, marking the body's preparation for potential pregnancy. It involves the interplay of hormones that regulate the growth and disintegration of the uterine lining (endometrium) and the release of an egg (ovulation) from the ovaries.

The menstrual cycle can be divided into three main phases:

1. Menstrual phase: The cycle begins with the onset of menstruation, where the thickened uterine lining is shed through the vagina, lasting typically for 3-7 days. This shedding occurs due to a decrease in estrogen and progesterone levels, which are hormones essential for maintaining the endometrium during the previous cycle.

2. Follicular phase: After menstruation, the follicular phase commences with the pituitary gland releasing follicle-stimulating hormone (FSH). FSH stimulates the growth of several ovarian follicles, each containing an immature egg. One dominant follicle usually becomes selected to mature and release an egg during ovulation. Estrogen levels rise as the dominant follicle grows, causing the endometrium to thicken in preparation for a potential pregnancy.

3. Luteal phase: Following ovulation, the ruptured follicle transforms into the corpus luteum, which produces progesterone and estrogen to further support the endometrial thickening. If fertilization does not occur within approximately 24 hours after ovulation, the corpus luteum will degenerate, leading to a decline in hormone levels. This drop triggers the onset of menstruation, initiating a new menstrual cycle.

Understanding the menstrual cycle is crucial for monitoring reproductive health and planning or preventing pregnancies. Variations in cycle length and symptoms are common among women, but persistent irregularities may indicate underlying medical conditions requiring further evaluation by a healthcare professional.

Danazol is a synthetic, orally active androgenic steroid with antigonadotropic properties. It is used primarily in the treatment of endometriosis, fibrocystic breast disease, and hereditary angioedema. Danazol works by suppressing the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary gland, which in turn inhibits the growth of ovarian tissue and reduces the production of estrogen and progesterone. This leads to a decrease in the symptoms associated with endometriosis and fibrocystic breast disease. In the case of hereditary angioedema, danazol helps prevent attacks by increasing the levels of a protein called C1 esterase inhibitor, which is necessary for regulating the immune system and preventing inflammation.

The common side effects of danazol include weight gain, acne, oily skin, increased hair growth, changes in menstrual cycle, decreased breast size, deepening of the voice, and emotional lability. Rare but serious side effects may include liver damage, blood clots, and adrenal gland problems. Danazol is contraindicated in pregnancy due to its potential virilizing effects on the fetus. It should be used with caution in individuals with a history of liver disease, heart disease, or seizure disorders.

The medical definition of danazol can be summarized as follows:

Danazol (dan-a-zole)

A synthetic androgenic steroid with antigonadotropic properties, used primarily in the treatment of endometriosis, fibrocystic breast disease, and hereditary angioedema. Danazol suppresses the release of FSH and LH from the pituitary gland, inhibiting ovarian tissue growth and reducing estrogen and progesterone production. In hereditary angioedema, danazol increases C1 esterase inhibitor levels to prevent attacks. Common side effects include weight gain, acne, increased hair growth, menstrual changes, decreased breast size, deepened voice, and emotional lability. Rare but serious side effects may involve liver damage, blood clots, or adrenal gland problems. Danazol is contraindicated in pregnancy due to potential virilizing effects on the fetus and should be used with caution in individuals with a history of liver disease, heart disease, or seizure disorders.

Megestrol is a synthetic progestin, which is a type of female hormone. It is used to treat certain types of cancer, such as breast cancer and endometrial cancer, in postmenopausal women. Megestrol works by blocking the effects of estrogen, a female hormone that can promote the growth of some breast and endometrial cancers.

Megestrol is also used to treat anorexia (loss of appetite) and cachexia (wasting syndrome) in people with AIDS or cancer. It works by increasing appetite and promoting weight gain.

Megestrol is available as a tablet or a suspension that is taken by mouth, usually two to four times a day. The dosage depends on the condition being treated and the individual patient's response to therapy. Common side effects of megestrol include nausea, vomiting, diarrhea, dizziness, headache, breast tenderness, and changes in menstrual periods.

It is important to note that megestrol can cause serious side effects, such as blood clots, fluid retention, and increased risk of certain types of infections. Patients should discuss the risks and benefits of megestrol therapy with their healthcare provider before starting treatment.

According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), alcohol-induced disorders of the nervous system are a category of conditions characterized by symptoms that are directly caused by alcohol use or withdrawal. These disorders include:

1. Alcohol-induced neurocognitive disorder: This condition is characterized by significant impairment in cognitive functioning, including difficulties with attention, memory, and executive functions, which are caused by alcohol use or withdrawal.
2. Alcohol-induced mood disorder: This condition is characterized by the presence of a mood disorder, such as depression or mania, that is directly caused by alcohol use or withdrawal.
3. Alcohol-induced anxiety disorder: This condition is characterized by the presence of an anxiety disorder, such as panic disorder or social anxiety disorder, that is directly caused by alcohol use or withdrawal.
4. Alcohol-induced sleep disorder: This condition is characterized by difficulty sleeping or maintaining sleep that is directly caused by alcohol use or withdrawal.
5. Alcohol-induced sexual dysfunction: This condition is characterized by the presence of sexual dysfunction, such as erectile dysfunction or decreased libido, that is directly caused by alcohol use or withdrawal.
6. Alcohol-induced movement disorder: This condition is characterized by the presence of abnormal movements, such as tremors or ataxia, that are directly caused by alcohol use or withdrawal.

It's important to note that in order for a diagnosis of an alcohol-induced disorder to be made, the symptoms must be severe enough to cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. Additionally, the symptoms must not be better explained by another medical condition or mental disorder.

Vacuum curettage is a medical procedure that involves the use of suction to remove tissue from the uterus. It is often used as a method of first-trimester abortion, or to treat abnormal uterine conditions such as miscarriage or retained placental tissue after childbirth. The cervix is dilated and a vacuum aspirator is inserted into the uterus to remove the contents using suction. This procedure may also be referred to as vacuum aspiration or suction curettage.

Embryo implantation is the process by which a fertilized egg, or embryo, becomes attached to the wall of the uterus (endometrium) and begins to receive nutrients from the mother's blood supply. This process typically occurs about 6-10 days after fertilization and is a critical step in the establishment of a successful pregnancy.

During implantation, the embryo secretes enzymes that help it to burrow into the endometrium, while the endometrium responds by producing receptors for the embryo's enzymes and increasing blood flow to the area. The embryo then begins to grow and develop, eventually forming the placenta, which will provide nutrients and oxygen to the developing fetus throughout pregnancy.

Implantation is a complex process that requires precise timing and coordination between the embryo and the mother's body. Factors such as age, hormonal imbalances, and uterine abnormalities can affect implantation and increase the risk of miscarriage or difficulty becoming pregnant.

Metrorrhagia is defined as uterine bleeding that occurs at irregular intervals, particularly between expected menstrual periods. It can also be described as abnormal vaginal bleeding that is not related to the regular menstrual cycle. The amount of bleeding can vary from light spotting to heavy flow.

Metrorrhagia is different from menorrhagia, which refers to excessive or prolonged menstrual bleeding during the menstrual period. Metrorrhagia can be caused by various factors, including hormonal imbalances, uterine fibroids, polyps, endometrial hyperplasia, infection, pregnancy complications, and certain medications or medical conditions.

It is essential to consult a healthcare provider if you experience any abnormal vaginal bleeding to determine the underlying cause and receive appropriate treatment.

Postcoital hormonal contraceptives, also known as emergency contraceptives, are methods used to prevent pregnancy after sexual intercourse has already occurred. These contraceptives contain hormones and are intended for use in emergency situations where regular contraception has failed or was not used, such as in cases of condom breakage or unprotected sex.

The most common type of postcoital hormonal contraceptive is the emergency contraceptive pill (ECP), which contains a high dose of synthetic progestin or a combination of progestin and estrogen. The ECP works by preventing ovulation, inhibiting fertilization, or altering the lining of the uterus to prevent implantation of a fertilized egg.

The ECP is most effective when taken as soon as possible after unprotected sex, ideally within 72 hours, but may still be effective up to 120 hours (5 days) after intercourse. However, the effectiveness of the ECP decreases over time, and it is not as effective as regular methods of contraception.

It's important to note that postcoital hormonal contraceptives are not intended for routine use as a primary method of contraception and should only be used in emergency situations. They do not protect against sexually transmitted infections (STIs) and should not be used as a substitute for regular condom use or other forms of protection.

If you have any concerns about postcoital hormonal contraceptives or need advice on the best method of contraception for you, it's important to speak with a healthcare provider.

The Fallopian tubes, also known as uterine tubes or oviducts, are a pair of slender tubular structures in the female reproductive system. They play a crucial role in human reproduction by providing a passageway for the egg (ovum) from the ovary to the uterus (womb).

Each Fallopian tube is typically around 7.6 to 10 centimeters long and consists of four parts: the interstitial part, the isthmus, the ampulla, and the infundibulum. The fimbriated end of the infundibulum, which resembles a fringe or frill, surrounds and captures the released egg from the ovary during ovulation.

Fertilization usually occurs in the ampulla when sperm meets the egg after sexual intercourse. Once fertilized, the zygote (fertilized egg) travels through the Fallopian tube toward the uterus for implantation and further development. The cilia lining the inner surface of the Fallopian tubes help propel the egg and the zygote along their journey.

In some cases, abnormalities or blockages in the Fallopian tubes can lead to infertility or ectopic pregnancies, which are pregnancies that develop outside the uterus, typically within the Fallopian tube itself.

I apologize for any confusion, but "Algestone" is not a recognized medical term or drug name in common usage. It's possible that there might be some misunderstanding or miscommunication regarding the term. If you have more context or information about where this term came from, I'd be happy to help you try to clarify it.

However, if you are referring to "Algestone acetonide," it is a synthetic corticosteroid used in some medical creams and gels for its anti-inflammatory and antipruritic (anti-itching) properties. It's commonly used to treat skin conditions such as eczema, dermatitis, and psoriasis.

If you have any further questions or need more information about a specific medical topic, please don't hesitate to ask!

Glucocorticoids are a class of steroid hormones that are naturally produced in the adrenal gland, or can be synthetically manufactured. They play an essential role in the metabolism of carbohydrates, proteins, and fats, and have significant anti-inflammatory effects. Glucocorticoids suppress immune responses and inflammation by inhibiting the release of inflammatory mediators from various cells, such as mast cells, eosinophils, and lymphocytes. They are frequently used in medical treatment for a wide range of conditions, including allergies, asthma, rheumatoid arthritis, dermatological disorders, and certain cancers. Prolonged use or high doses of glucocorticoids can lead to several side effects, such as weight gain, mood changes, osteoporosis, and increased susceptibility to infections.

**Norgestrel** is a synthetic form of the naturally occurring hormone **progesterone**. It is a type of **progestin**, which is often used in various forms of hormonal birth control to prevent pregnancy. Norgestrel works by thickening cervical mucus, making it more difficult for sperm to reach and fertilize an egg. Additionally, norgestrel can also prevent ovulation (the release of an egg from the ovaries) and thin the lining of the uterus, which makes it less likely for a fertilized egg to implant.

Norgestrel is available in various forms, such as oral contraceptive pills, emergency contraceptives, and hormonal intrauterine devices (IUDs). It's essential to consult with a healthcare provider before starting any hormonal birth control method to discuss potential benefits, risks, and side effects.

Here are some medical definitions related to norgestrel:

1. **Progestin**: A synthetic form of the naturally occurring hormone progesterone, used in various forms of hormonal birth control and menopausal hormone therapy. Progestins can have varying levels of androgenic, estrogenic, and anti-estrogenic activity. Norgestrel is a type of progestin.
2. **Progesterone**: A naturally occurring steroid hormone produced by the ovaries during the second half of the menstrual cycle. Progesterone plays a crucial role in preparing the uterus for pregnancy and maintaining a healthy pregnancy. Norgestrel is a synthetic form of progesterone.
3. **Hormonal birth control**: A method of preventing pregnancy that uses hormones to regulate ovulation, thicken cervical mucus, or thin the lining of the uterus. Hormonal birth control methods include oral contraceptive pills, patches, rings, injections, implants, and intrauterine devices (IUDs).
4. **Emergency contraception**: A form of hormonal birth control used to prevent pregnancy after unprotected sex or contraceptive failure. Emergency contraception is typically more effective when taken as soon as possible after unprotected intercourse, but it can still be effective up to 120 hours afterward. Norgestrel is one of the active ingredients in some emergency contraceptive pills.
5. **Menopausal hormone therapy (MHT)**: A form of hormone replacement therapy used to alleviate symptoms associated with menopause, such as hot flashes and vaginal dryness. MHT typically involves using estrogen and progestin or a selective estrogen receptor modulator (SERM). Norgestrel is a type of progestin that can be used in MHT.
6. **Androgenic**: Describing the effects of hormones, such as testosterone and some progestins, that are associated with male characteristics, such as facial hair growth, deepening of the voice, and increased muscle mass. Norgestrel has weak androgenic activity.
7. **Estrogenic**: Describing the effects of hormones, such as estradiol and some selective estrogen receptor modulators (SERMs), that are associated with female characteristics, such as breast development and menstrual cycles. Norgestrel has weak estrogenic activity.
8. **Antiestrogenic**: Describing the effects of hormones or drugs that block or oppose the actions of estrogens. Norgestrel has antiestrogenic activity.
9. **Selective estrogen receptor modulator (SERM)**: A type of drug that acts as an estrogen agonist in some tissues and an estrogen antagonist in others. SERMs can be used to treat or prevent breast cancer, osteoporosis, and other conditions associated with hormonal imbalances. Norgestrel is not a SERM but has antiestrogenic activity.
10. **Progestogen**: A synthetic or natural hormone that has progesterone-like effects on the body. Progestogens can be used to treat various medical conditions, such as endometriosis, uterine fibroids, and irregular menstrual cycles. Norgestrel is a type of progestogen.
11. **Progesterone**: A natural hormone produced by the ovaries during the second half of the menstrual cycle. Progesterone prepares the uterus for pregnancy and regulates the menstrual cycle. Norgestrel is a synthetic form of progesterone.
12. **Progestin**: A synthetic hormone that has progesterone-like effects on the body. Progestins can be used to treat various medical conditions, such as endometriosis, uterine fibroids, and irregular menstrual cycles. Norgestrel is a type of progestin.
13. **Progestational agent**: A drug or hormone that has progesterone-like effects on the body. Progestational agents can be used to treat various medical conditions, such as endometriosis, uterine fibroids, and irregular menstrual cycles. Norgestrel is a type of progestational agent.
14. **Progestogenic**: Describing the effects of hormones or drugs that mimic or enhance the actions of progesterone. Norgestrel has progestogenic activity.
15. **Progesterone receptor modulator (PRM)**: A type of drug that binds to and activates or inhibits the progesterone receptors in the body. PRMs can be used to treat various medical conditions, such as endometriosis, uterine fibroids, and breast cancer. Norgestrel is a type of PRM.
16. **Progestogenic activity**: The ability of a drug or hormone to mimic or enhance the actions of progesterone in the body. Norgestrel has progestogenic activity.
17. **Progesterone antagonist**: A drug that blocks the action of progesterone in the body. Progesterone antagonists can be used to treat various medical conditions, such as endometriosis, uterine fibroids, and breast cancer. Norgestrel is not a progesterone antagonist.
18. **Progestogenic antagonist**: A drug that blocks the action of progestogens in the body. Progestogenic antagonists can be used to treat various medical conditions, such as endometriosis, uterine fibroids, and breast cancer. Norgestrel is not a progesterone antagonist.
19. **Progesterone agonist**: A drug that enhances the action of progesterone in the body. Progesterone agonists can be used to treat various medical conditions, such as endometriosis, uterine fibroids, and breast cancer. Norgestrel is a progesterone agonist.
20. **Progestogenic agonist**: A drug that enhances the action of progestogens in the body. Progesterogenic agonists can be used to treat various medical conditions, such as endometriosis, uterine fibroids, and breast cancer. Norgestrel is a progesterone agonist.
21. **Progesterone receptor modulator**: A drug that binds to the progesterone receptor and can either activate or inhibit its activity. Progesterone receptor modulators can be used to treat various medical conditions, such as endometriosis, uterine fibroids, and breast cancer. Norgestrel is a progesterone receptor modulator.
22. **Progestogenic receptor modulator**: A drug that binds to the progesterone receptor and can either activate or inhibit its activity. Progesterogenic receptor modulators can be used to treat various medical conditions, such as endometriosis, uterine fibroids, and breast cancer. Norgestrel is a progesterone receptor modulator.
23. **Progestin**: A synthetic form of progesterone that is used in hormonal contraceptives and menopausal hormone therapy. Progestins can be either progesterone agonists or antagonists, depending on their chemical structure and activity at the progesterone receptor. Norgestrel is a progestin.
24. **Progesterone antagonist**: A drug that binds to the progesterone receptor and inhibits its activity. Progesterone antagonists can be used to treat various medical conditions, such as endometriosis, uterine fibroids, and breast cancer. Norgestrel is not a progesterone antagonist.
25. **Progestogenic antagonist**: A drug that binds to the progesterone receptor and inhibits its activity. Progesterogenic antagonists can be used to treat various medical conditions, such as endometriosis, uterine fibro

Oxytocics are a class of medications that stimulate the contraction of uterine smooth muscle. They are primarily used in obstetrics to induce or augment labor, and to control bleeding after childbirth. Oxytocin is the most commonly used oxytocic and is naturally produced by the posterior pituitary gland. Synthetic forms of oxytocin, such as Pitocin, are often used in medical settings to induce labor or reduce postpartum bleeding. Other medications with oxytocic properties include ergometrine and methylergometrine. It's important to note that the use of oxytocics should be monitored carefully as overuse can lead to excessive uterine contractions, which may compromise fetal oxygenation and increase the risk of uterine rupture.

A legal abortion is the deliberate termination of a pregnancy through medical or surgical means, carried out in accordance with the laws and regulations of a particular jurisdiction. In countries where abortion is legal, it is typically restricted to certain circumstances, such as:

* To protect the life or health of the pregnant person
* In cases of fetal anomalies that are incompatible with life outside the womb
* When the pregnancy is the result of rape or incest
* When the continuation of the pregnancy would pose a significant risk to the physical or mental health of the pregnant person

The specific circumstances under which abortion is legal, as well as the procedures and regulations that govern it, vary widely from one country to another. In some places, such as the United States, abortion is protected as a fundamental right under certain conditions; while in other countries, such as those with highly restrictive abortion laws, it may only be allowed in very limited circumstances or not at all.

Menorrhagia is a medical term used to describe abnormally heavy or prolonged menstrual periods. It's often characterized by the loss of an excessive amount of menstrual blood (usually more than 80 ml) and can last longer than normal, typically over seven days. This condition can have significant impacts on a woman's quality of life, causing fatigue, distress, and restrictions in daily activities due to the need for frequent pad or tampon changes.

The causes of menorrhagia are varied and can include hormonal imbalances, uterine fibroids or polyps, endometrial hyperplasia, pelvic inflammatory disease, pregnancy complications, certain medications, and underlying medical conditions such as coagulopathies or thyroid disorders. In some cases, the cause may remain undetermined even after a thorough evaluation.

Treatment options for menorrhagia depend on the underlying cause and range from medication management with hormonal therapies, nonsteroidal anti-inflammatory drugs (NSAIDs), or tranexamic acid to procedural interventions like endometrial ablation, hysteroscopic resection of polyps or fibroids, or ultimately hysterectomy in severe cases. It is essential for individuals experiencing menorrhagia to consult with their healthcare provider to determine the best course of action based on their specific situation and medical history.

Corticosterone is a hormone produced by the adrenal gland in many animals, including humans. It is a type of glucocorticoid steroid hormone that plays an important role in the body's response to stress, immune function, metabolism, and regulation of inflammation. Corticosterone helps to regulate the balance of sodium and potassium in the body and also plays a role in the development and functioning of the nervous system. It is the primary glucocorticoid hormone in rodents, while cortisol is the primary glucocorticoid hormone in humans and other primates.

A pessary is a medical device that is inserted into the vagina to provide support for the uterus, vaginal vault, or bladder. It is often used in the management of pelvic organ prolapse, urinary incontinence, and other gynecological conditions. Pessaries come in various shapes and sizes, and they are typically made of silicone, rubber, or plastic. They can be worn for extended periods of time and are usually removable and cleanable. The selection and fitting of a pessary should be performed by a healthcare professional, such as a gynecologist or nurse midwife.

'Clostridium sordellii' is a gram-positive, spore-forming, anaerobic rod-shaped bacterium. It is part of the normal microbiota found in the human and animal gastrointestinal tract. However, it can cause severe and potentially fatal infections in humans, such as sepsis, myonecrosis (gas gangrene), and soft tissue infections. These infections are more commonly associated with contaminated wounds, surgical sites, or drug use (particularly black tar heroin). The bacterium produces powerful toxins that contribute to its virulence and can lead to rapid progression of the infection. Immediate medical attention is required for proper diagnosis and treatment, which typically involves antibiotics, surgical debridement, and supportive care.

Dexamethasone is a type of corticosteroid medication, which is a synthetic version of a natural hormone produced by the adrenal glands. It is often used to reduce inflammation and suppress the immune system in a variety of medical conditions, including allergies, asthma, rheumatoid arthritis, and certain skin conditions.

Dexamethasone works by binding to specific receptors in cells, which triggers a range of anti-inflammatory effects. These include reducing the production of chemicals that cause inflammation, suppressing the activity of immune cells, and stabilizing cell membranes.

In addition to its anti-inflammatory effects, dexamethasone can also be used to treat other medical conditions, such as certain types of cancer, brain swelling, and adrenal insufficiency. It is available in a variety of forms, including tablets, liquids, creams, and injectable solutions.

Like all medications, dexamethasone can have side effects, particularly if used for long periods of time or at high doses. These may include mood changes, increased appetite, weight gain, acne, thinning skin, easy bruising, and an increased risk of infections. It is important to follow the instructions of a healthcare provider when taking dexamethasone to minimize the risk of side effects.

Ethinyl estradiol is a synthetic form of the hormone estrogen that is often used in various forms of hormonal contraception, such as birth control pills. It works by preventing ovulation and thickening cervical mucus to make it more difficult for sperm to reach the egg. Ethinyl estradiol may also be used in combination with other hormones to treat menopausal symptoms or hormonal disorders.

It is important to note that while ethinyl estradiol can be an effective form of hormonal therapy, it can also carry risks and side effects, such as an increased risk of blood clots, stroke, and breast cancer. As with any medication, it should only be used under the guidance and supervision of a healthcare provider.

Leiomyoma is a benign (non-cancerous) tumor that originates from the smooth muscle cells. It most commonly occurs in the uterus, where it is also known as a fibroid, but can also develop in other parts of the body such as the skin, gastrointestinal tract, and genitourinary system. Leiomyomas are typically slow-growing and often cause no symptoms, although they can lead to various complications depending on their size and location. Treatment options for leiomyomas include surveillance, medication, or surgical removal.

Medical Definition:

Mineralocorticoid Receptors (MRs) are a type of nuclear receptor protein that are activated by the binding of mineralocorticoid hormones, such as aldosterone. These receptors are expressed in various tissues and cells, including the kidneys, heart, blood vessels, and brain.

When activated, MRs regulate gene expression related to sodium and potassium homeostasis, water balance, and electrolyte transport. This is primarily achieved through the regulation of ion channels and transporters in the distal nephron of the kidney, leading to increased sodium reabsorption and potassium excretion.

Abnormalities in mineralocorticoid receptor function have been implicated in several diseases, including hypertension, heart failure, and primary aldosteronism.

Mifepristone is licensed in Ireland for use of abortions up to 12 weeks since it was legalised in 2018. Mifepristone is not ... In Denmark, mifepristone was used in between 3,000 and 4,000 of just over 15,000 abortions in 2005. Mifepristone was approved ... Mifepristone was approved in Israel in 1999. Clinical trials of mifepristone in China began in 1985. In October 1988, China ... The approval of mifepristone under subsection H included a black box warning. Outside the United States, mifepristone is ...
Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor. In ... Korlym (mifepristone) is a small-molecule progesterone and glucocorticoid antagonist. It blocks the binding of cortisol to its ... Korlym (mifepristone) is a small-molecule progesterone and glucocorticoid antagonist. It is a selective antagonist of the ... addition, mifepristone appears to have little or no affinity for estrogen, muscarinic, histaminic or monoamine receptors. ...
Mifepristone (Korlym): learn about side effects, dosage, special precautions, and more on MedlinePlus ... Mifepristone comes as a tablet to take by mouth. It is usually taken once a day with a meal. Take mifepristone at around the ... Do not take mifepristone if you are pregnant or plan to become pregnant. Mifepristone can cause loss of the pregnancy. You must ... Before taking mifepristone,. *tell your doctor if you are allergic to mifepristone, any other medications, or any of the ...
Articles tagged Mifepristone. Federal court backs pro-life laws in West Virginia but will hear case against abortion telemed ...
RU-486 is the code name for an abortion drug that is now widely known as Mifepristone. ... RU-486 (Mifepristone). RU-486 is the code name for an abortion drug that is now widely known as Mifepristone. This drug was ... Mifepristone has also been demonstrated to be highly effective as a post-coital contraceptive (morning after pill) when ...
DNC Statement on Texas Ruling on Mifepristone. April 7, 2023. * ... to move to block access to the abortion pill mifepristone, DNC ...
Staphylococcus also known as "staph" is section of the MRSA name. The most common Urinary Tract infection occur from:. Despite this data, I unknowingly was prescribed a medicine that almost require me to pay my life. During the analyze, the desk gets into and out with the reader, a ring-shaped device that completely surrounds the desk. Our son would cough at night, often to vomiting. However Despite the convincing results reported towards the Boston medical society in December 1844 the newest method has not been adopted by other dentists. The last three symptoms could be atypical, or without an origin. Ive had miraculous strategies to prayer; Im confident God can heal:. The inflammation invades the glomerulus (vascular bulb-like units inside the nephrons) and disturbs the kidneys power to filter the blood for wastes. Oral decongestants (Sudafed) are longer lasting but have many side effects (fast heartbeat, excitability) and could not be effective in the elderly. However, which is not ...
Entries Tagged mifepristone. Pro-life blog buzz 6-23-15. by Kelli Abstinence Clearinghouse points out how the Boston Globe ... Apparently, Health Canada has been considering approval of mifepristone (known as RU-486) since December 2012," as "the drug is ...
Ahead of the Supreme Courts decision on access to mifepristone, an anti-abortion advocate contends that the most commonly used ...
Mifepristone is a drug intended to terminate a pregnancy in its early stages. Planned Parenthoods use of videoconferencing to ... Still in the company of the clinic nurse, the patient then takes the mifepristone with her doctor watching, and receives the ... In order for a woman to receive mifepristone via videoconference, she must first go to her local Planned Parenthood and undergo ... Planned Parenthood clinics in Iowa have introduced a program that enables mifepristone, also known as RU-486 or the "abortion ...
Early medical abortion with mifepristone 200 mg followed by misoprostol is highly effective and safe. ... First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review Contraception. 2013 Jan;87(1):26 ... Background: The dose of mifepristone approved by most government agencies for medical abortion is 600 mg. Our aim was to ... Conclusions: Early medical abortion with mifepristone 200 mg followed by misoprostol is highly effective and safe. ...
This is example text for design purposes...Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt.. Donate Today. ...
http://www.womenonwaves.org/en/page/6995/safe-abortion-for-turkey ...
Toxicity. Mifepristone has very high chronic toxicity.. Risk. The use of mifepristone (sales data Sweden 2020) has been ... Mifepristone bioaccumulation potential can therefore be considered to be low (BCF , 500) and the phrase "Mifepristone has low ... Persistence: The DT50/DT90 values for Mifepristone are 4.5/14.9 days (water phase), 72.1/239.0 days (sediment phase) and 14.3/ ... Bioaccumulation: Experimental Log Kow is 4.61, however the estimated bioconcentration factors derived from the Mifepristone ...
Everything you need to know about Mifepristone and Misoprostol abortion pills. The abortion pill is safe, effective, affordable ... Side effects of Mifepristone and Misoprostol After inducing an abortion with Mifepristone and Misoprostol tablets, you can ... Mifepristone & Misoprostol Abortion Pills. Everything you need to know about Mifepristone and Misoprostol abortion pills. The ... About Mifepristone and Misoprostol tablets The abortion pills are a combination of two medicines: Mifepristone and Misoprostol ...
mifepristone from Neuroscience News features breaking science news from research labs, scientists and colleges around the world ... Women who use mifepristone for a medical abortion are at risk of severe hemorrhage if they do not complete the procedure with ...
Are allergic to mifepristone, misoprostol or other prostaglandins.. Mifeprex cannot be used in cases of confirmed or suspected ... Are allergic to mifepristone, misoprostol or other prostaglandins.. Mifeprex cannot be used in cases of confirmed or suspected ... Mifeprex , Mifepristone , Abortion Pill , RU486 , Early Option Pill. FDA approved since 2000. A safe and effective non-surgical ... Mifeprex* (mifepristone) is the first Food and Drug Administration (FDA)-approved early option pill for non-surgical abortion. ...
In addition, a fatal case of C. sordellii toxic shock syndrome after medical abortion with mifepristone and misoprostol was ... Cases potentially associated with use of mifepristone or misoprostol should also be reported through the FDA MedWatch system ... Clostridium sordellii Toxic Shock Syndrome After Medical Abortion with Mifepristone and Intravaginal Misoprostol --- United ... mifepristone, formerly RU-486; Danco Laboratories, New York, New York) and intravaginal misoprostol (1). Two of these deaths ...
CT Politics: CT reacts to Texas judges mifepristone ruling by CT Mirror Newsletters April 14, 2023 @ 7:00 pm. Updated May 26, ...
LLCs labeling of mifepristone (trade name Mifeprex, also known as RU-486). Mifeprex was approved in 2000 for the termination ... New Safety Changes For Mifepristone. The Food and Drug Administration will announce today important new safety changes to the ... New Safety Changes For Mifepristone. The Food and Drug Administration will announce today important new safety changes to the ... Home » FDA Important Labeling Changes for Mifepristone. FDA Important Labeling Changes for Mifepristone. Posted: November 15, ...
Ahead of oral arguments in a federal appeals court over access to mifepristone, more than 150 people shared stories with NPR ... She took mifepristone at a doctors office, then went home to take the misoprostol. The next year, she was able to leave the ... Physically, taking mifepristone and misoprostol was a seriously painful experience for some and caused few symptoms for others ... Medical staff told her she could take a combination of mifepristone and misoprostol to prompt her body to expel the tissue. Or ...
5th Circuit Court of Appeals panel upheld restrictions on the abortion pill mifepristone, finding that the FDA didnt take ... They argued mifepristone has side effects, even though the complication rate is very low, and that they as doctors have had to ... A group in Texas sued the FDA over its approval of mifepristone. Today, a panel of judges at the 5th Circuit Court of Appeals ... SIMMONS-DUFFIN: ...Mifepristone - still available.. CHANG: OK, so no immediate impact. Then what did the federal appeals court ...
https://apnews.com/article/supreme-court-abortion-pill-mifepristone-access-f781488016640bf571faf36096339ea4. _________________ ...
News Tip: Legal Experts Available to Comment on SCOTUS Mifepristone Ruling. Media Contact:. Jeannie Naujeck. jeannie.naujeck@ ... and Danco Laboratories to block a Texas federal judges ruling suspending the FDAs 2000 approval of mifepristone, one of two ...
1998 One in Two Ob/Gyns Say They are Likely to Offer Mifepristone (RU-486) If Approved by FDA, And Almost Half Who Do Not Now ... www.kff.org/womens-health-policy/will-1999-be-the-year-for-mifepristone/ class=see-more light-beige no-float inline-readmore ... One in Two Ob/Gyns Say They are Likely to Offer Mifepristone (RU-486) If Approved by FDA, And Almost Half Who Do Not Now ... Will 1999 Be The Year For Mifepristone (Ru-486)? And, An Update on Womens Other Options for Very Early Abortion. Facebook ...
Supreme Court urging the justices to overturn an appellate court decision that would roll back access to mifepristone, one of ...
Pharmacy-Dispensed Mifepristone Is Proven Safe and Effective. Research has shown that pharmacist dispensing of medication ... "This is just a bunch of paperwork that doesnt add any value," said Moore, who admitted it may be a while before mifepristone ... Mifepristone remains within the FDAs highly restrictive Risk Evaluation and Mitigation Strategies (REMS) drug safety program, ... In a statement on Monday, March 6, the pharmacy chain vowed to offer mifepristone where it is still possible to do so. ...
Mifepristone (RU486), a clinical abortion agent and potential endocrine disruptor, binds to progestin and glucocorticoid ... Mifepristone (RU486), a clinical abortion agent and potential endocrine disruptor, binds to progestin and glucocorticoid ... Effects of long term antiprogestine mifepristone (RU486) exposure on sexually dimorphic lncRNA expression and gonadal ...
... buy CYTOTEC price mifepristone with misoprostal)) Beasd on prescription, medicine will be given ((@) woman who is sexually ac ... buy #Mifepristone and #misoprostol #online #Jeddah,#abortion #pills #cytotec #available in Jeddah #buy #abortion #pills #in # ... Both abortion pills, mifepristone and misoprostol are usually used in order to terminate a pregnancy. Mifepristone causes the ... buy mifepristone and misoprostol in Riyadh buy Cytotec pills in Riyadh, buy abortion pills in Jeddah ,buy mifepristone and ...

No FAQ available that match "mifepristone"

No images available that match "mifepristone"